HEather BResch

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were under heavy selling pressure Wednesday morning after the U.S. Food and Drug Administration granted approval for a rival product. The FDA granted approval to Mylan N.V. (NASDAQ: MYL) to sell a generic version of Teva's Copaxone...

Mylan N.V. (NASDAQ: MYL), which has faced a plethora of lawsuits in the past over its EpiPen, is now being saddled with another lawsuit, although this time around the parties involved go beyond the company and the plaintiffs. EpiPen And Its Legal Tussle EpiPen, or an epinephrine auto injector is...

Mylan NV (NASDAQ: MYL)'s EpiPen controversy, in which the company may have been unjustified in raising the cost of its life saving device over the years, is far from over. Even though Mylan's CEO Heather Bresch sat in front of a U.S. House Oversight panel this week to defend the company's business...

Bill George, a Harvard Business School senior fellow and ex-chairman of Medtronic PLC (NYSE: MDT) has some harsh words for Mylan NV (NASDAQ: MYL)'s CEO Heather Bresch. Speaking as a guest on CNBC's "Squawk On The Street" on Wednesday, George said that Bresch could be in for a "rough time" as she is...

Mylan NV (NASDAQ: MYL)'s CEO Heather Bresch could face the wrath of the U.S. Congress on Wednesday given the company's practice of boosting the price of its potential life-saving EpiPen. According to a Bloomberg report, Robert Coury, Bresch's boss, won't be taking the stand on Wednesday. Coury,...

Pharmaceutical companies have been in the spotlight for quite some time now, mainly due to the price-gouging phenomenon. Mylan NV (NASDAQ: MYL) became the central actor in the latest of many chapters in this scandal story, after presidential candidate Hillary Clinton and the White House publicly...

Mylan NV (NASDAQ: MYL) has been making the wrong kind of headlines this week. Democratic presidential nominee Hillary Clinton singled out Mylan for its 400 percent increase in the price of EpiPens in recent years. “It’s wrong when drug companies put profits ahead of patients, raising...

Mylan NV (NASDAQ: MYL) has received overwhelming criticism, even inciting mention from Hillary Clinton, for increasing the price of its life-saving EpiPen product 400 percent while raising the Mylan CEO’s salary by 600 percent. Company shares have begun to rebound Thursday, however, due to...

Mylan NV (NASDAQ: MYL), the seller of a potentially life-saving medical device called EpiPen, saw its share of controversy this week when officials of the U.S. government called into question the company's pricing policies. In 2008, the EpiPen sold for around $100 but has since risen six...

Mylan NV (NASDAQ: MYL)'s 400 percent price hike to a potentially life-saving device was called into question by members of the U.S. government this week. Mylan, the maker of EpiPen, an epinephrine auto injector used in emergency cases by individuals suffering a severe allergic reaction,...

Mylan NV (NASDAQ: MYL) is the latest pharmaceutical company to come under government scrutiny. Mylan is the maker of a device that provides epinephrine in the event of anaphylaxis — also known as the EpiPen. According to Fortune, Mylan built the EpiPen from a "weakening enterprise" in 2007 to...